行情

CERS

CERS

Cerus Corp
NASDAQ

实时行情|Nasdaq Last Sale

7.10
-0.18
-2.47%
盘前: 7.22 +0.12 +1.69% 08:52 08/07 EDT
开盘
7.24
昨收
7.28
最高
7.25
最低
6.91
成交量
1.86万
成交额
--
52周最高
7.56
52周最低
2.710
市值
11.64亿
市盈率(TTM)
-16.1034
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CERS价格均价为9.13,最高价位10.00,最低价为8.00。

EPS

CERS 新闻

更多
Cerus Corporation (CERS) Q2 2020 Earnings Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the CERUS Corp. Q2 2020 Earnings Conference Call. With me on the call are Obi Greenman, Cerus' President and Chief Executive Officer; Dr. Nina Mufti, Cerus' Vice President, Development and Red Bl
Motley Fool · 2天前
Cerus EPS beats by $0.02, beats on revenue
Cerus (NASDAQ:CERS): Q2 GAAP EPS of -$0.09 beats by $0.02. Revenue of $26.8M (+47.2% Y/Y) beats by $6.21M. Shares +5.5%. Press Release
seekingalpha · 2天前
Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates
Cerus (CERS) delivered earnings and revenue surprises of 10.00% and 0.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 2天前
Cerus Reaffirms FY20 Sales Guidance of $89M-$93M Vs. $112.8M Est.
Benzinga · 2天前
Cerus Q2 EPS $(0.09) Beats $(0.11) Estimate, Sales $26.80M Beat $25.89M Estimate
Cerus (NASDAQ:CERS) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 30.77 percent increase over losses of $(0.13) per share from the same
Benzinga · 2天前
Cerus Corporation Announces Record Second Quarter 2020 Results
Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2020.
Business Wire · 2天前
Cerus Shares Spike Higher; President Trump To Participate In Roundtable On Donating Plasma
Benzinga · 07/30 17:36
Cerus Wins 5-Year Tender Award By Hong Kong Red Cross Blod Transfusion Service For INTERCEPT Blood Systems, No Terms Disclosed
Benzinga · 07/30 12:32

所属板块

医疗设备、用品及经销
-0.94%
医疗设备和用品
-0.94%

热门股票

代码
价格
涨跌幅

CERS 简况

Cerus Corporation主要提供生物医药产品。该公司开发和商业化用于确保血液安全的INTERCEPT血液系统。该公司通过血液安全部门运营。其INTERCEPT血液系统是基于控制生物复制的技术研发的,旨在减少捐献的血液成分(用于输血的血源)中的血源性病原体。INTERCEPT血液系统旨在靶向血源性病原体并使血源性病原体失去活性,同时保持血小板、血浆和红细胞等输血产品的治疗特性。这些血源性病原体包括病毒(人类免疫缺陷病毒(HIV)、西尼罗河病毒、严重急性呼吸综合症(SARS)病毒,以及乙型和丙型肝炎病毒等)、细菌和寄生虫以及有害的白细胞等。该公司的INTERCEPT血液系统用于确保血液成分的安全,包括血浆、血小板和红细胞。
展开

微牛提供Cerus Corporation(NASDAQ-CERS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CERS股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CERS股票基本功能。